Member Info for Chrisatrdg

Good to get updated on the Peruvian deal which at todays current $ rate will add 21% to current Market Cap.

I am invested in INFA & today made a modest investment of 100,000 shares at 0.43 post 12.00 but note that it was not included in the share postings today.Hopefully I have made the right decision.GLA

Summit Therapeutics (SMMT) Presents at 19th Annual BIO CEO & Investor Conference The following slide deck was published by Summit Therapeutics in conjunction with this event. http://seekingalpha.com/article/4045839-summit-therapeutics-smmt-presents-19th-annual-bio-ceo-and-investor-conference?auth_param=14cn1a:1ca6ktq:74a07dd47866705e2be6076947b58816&uprof=46&dr=1

Hi gmcc - I know where you are coming from & also in the same boat as you & invested 7 years this month but the next 6 months should allow some de-risking for me.

13 Feb 2017 BIO CEO & Investor Conference (New York) - Erik Ostrowski CFO - webcast 3.30 UK time today (correction for time). http://www.summitplc.com/investors/presentations/

13 Feb 2017 BIO CEO & Investor Conference (New York) - Erik Ostrowski CFO - webcast 3.00 UK time today http://www.summitplc.com/investors/presentations/

Per waterloo01 from the other board & for me best read I have seen for some time including points on de-risking: http://seekingalpha.com/article/4044252-play-runup-summit-therapeutics'To conclude, I believe the runup in share price could continue into the 24 week biopsy data in the PhaseOut DMD trial. Investors establishing a position in the near term could see a 50% return or more. Data for the phase 2 trial of ridinilazole could also provide material upside, although I believe Wall Street is focused on ezutromid as the primary value driver.'

I note that as I type NASDAQ is at £1.88 & AIM seems to be responding - RNS soon ?

Based on the quick recent responses this afternoon it just shows the various views but one thing we do agree on is that provided the science holds we are likely to make a significant return in the next two years.

It is now down 9.38% & at $1.25 to the £ is £1.73 now below AIM.It seems to me both markets follow each other up & down.Markets are generally down today possible the Trump effect again.Hopefully AIM will not fall again Friday but it is mainly day traders taking profits also C-Diff not till H1 2018 may have dampened things down once RNS was fully digested. Just a thought.

Summit Therapeutics aiming to 'make a big impact' with new drug Ridinilazole http://www.proactiveinvestors.co.uk/companies/stocktube/6847/summit-therapeutics-aiming-to-make-a-big-impact-with-new-drug-ridinilazole-6847.html

Hi Free-Money - Been following CNN today/evening showing downturn in US markets I believe this has been one of the drivers.The Dow dropped below 20,000 worst movement in US since last October across all markets - partly The Trump effect re immigration which has created uncertainty.

I sympathise with EP & understand the arguments of Free-Money but it was galling to see my investment go down £6.5k overnight being 20% of paper profit to-date.On 25/02/2017 I will have been invested in Summit 7 years starting in 2010 with 1,250 (new money) for £623 so it has been a long time & now own 0.06%.Summit is a pump & dump share for which many traders have made loads of money but for us long time investors this has to be our year provided the science holds & it is that which keeps me going.

Parent Project MD @ParentProjectMD Join PPMD & @Summitplc on Wed, Jan 25 @ 11am ET for a webinar on utrophin modulation approach for #Duchenne: http://community.parentprojectmd.org/events/upcoming-webinar-summit-s-utrophin-modulation-program … Eastern time is 5 hrs behind the UK above time in the UK is 4pm this afternoon. Further exposure for Summit.

NASDAQ close at 10.99 using $1.23 equates to £1.79 & which at current range on AIM of £1.55 to £1.67 makes it ahead of AIM so can we expect a breakout in UK to follow US. Would be good if SP in UK does follow US would be a good start to the climb back.

Summit Therapeutics Plc breached its 50 day moving average in a Bullish Manner : SUMM-GB : January 12, 2017 http://www.capitalcube.com/blog/index.php/summit-therapeutics-plc-breached-its-50-day-moving-average-in-a-bullish-manner-summ-gb-january-12-2017/

Reported 27/12 further cover of Summit giving us more exposure: Post Earnings Coverage as Summit Therapeutics Q3 Net Loss Narrowed; Entered into Agreement with Sarepta http://finance.yahoo.com/news/post-earnings-coverage-summit-therapeutics-131500281.html

http://www.fiercebiotech.com/biotech/as-dust-settles-cures-what-will-it-mean-for-biopharma-r-d Could be very useful Behind the headline dollar figures lie some pretty drastic changes for pharma R&D. Cures aims to speed up the times it takes new medicines to get to patients, embed patient groups more firmly in the FDA review process, and—more controversially—allow urgently needed new drugs to be approved using different standards from those used at the moment.Per waterloo01 other board 'As the dust settles on Cures, what will it mean for biopharma R&D?'

Well done FootieladBaz another topped up last week on the other board also at £1.50 so you are in good company.I think if I had the funds £1.50 does make a good top up point.

Thanks gmcc for your post today.With the SP back in the doldrums good to see maybe some good news soon.Regards PS Now showing as only Buy with the current SP ups & downs.